Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737282 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
A Phase 3 study, sponsored by Repros Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 175
- Enrollment target
NCT00737282: Clinical Trial Phase 3 study, sponsored by Repros Therapeutics.
NCT00737282 is a Phase 3 study that was terminated before completion, run by Repros Therapeutics. The registered enrollment target is 175 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00737282, a Phase 3 study, was terminated before completion, sponsored by Repros Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 175 participants
- Enrollment target
Study Summary
The safety of Proellex 25 and 50 mg administered once daily for three treatment cycles (four months each) will be evaluated.
Interventions
- DRUG Proellex 25 mg
- DRUG Proellex 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Why NCT00737282 stopped before completion
NCT00737282 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Proellex 25 mg is the first listed.
NCT00737282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00737282 about?
NCT00737282 is a clinical study titled "Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids". The safety of Proellex 25 and 50 mg administered once daily for three treatment cycles (four months each) will be evaluated.
What is the current status of trial NCT00737282?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 175 participants. The study started on 2008-10. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00737282?
The interventions under investigation include: Proellex 25 mg (DRUG), Proellex 50 mg (DRUG).
Who is sponsoring clinical trial NCT00737282?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00737282's enrollment target sits among peer trials
175 1440th of 2000 higher than 559 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia